Trial Profile
A Multicenter, Open-label Study of the Histone Deacetylase Inhibitor (HDACi) Abexinostat, in Combination With Ibrutinib, in Subjects With Relapsed or Refractory Lymphomas
Status:
Not yet recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 02 Dec 2015
Price :
$35
*
At a glance
- Drugs Abexinostat (Primary) ; Ibrutinib
- Indications Diffuse large B cell lymphoma; Follicular lymphoma; Peripheral T-cell lymphoma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Pharmacyclics
- 19 Nov 2015 Planned primary completion date changed from 1 Dec 2018 to 1 Jun 2020 as per NCT.
- 19 Nov 2015 Planned primary completion date changed from 1 Dec 2018 to 1 Jun 2020 as per NCT.
- 30 Oct 2015 New trial record